Personalized Bio-Engineered Human Hearts For All — Dr. Doris A. Taylor, Ph.D., CEO, Organamet Bio Inc.
Dr. Doris A. Taylor, Ph.D. is Chief Executive Officer of Organamet Bio Inc. (https://organametbio.com/) an early phase start-up committed to saving lives and reducing the cost of healthcare for those with heart disease. Organamet has a goal is to make personalized bio-engineered human hearts, available to all who need them, within 5 years, increasing availability and access to hearts, decreasing or eliminating need for immunosuppression, reducing total lifetime transplant costs, and improving quality of life.
Dr. Taylor was previously the Director, Regenerative Medicine Research and Director, Center for Cell and Organ Biotechnology, at the Texas Heart Institute in Houston, Texas, where she worked on the integration of regenerative medicine and tissue engineering.
Dr. Taylor has a Ph.D. in Pharmacology from UT Southwestern Medical Center, Dallas, Texas. She did her post-doctoral studies at Albert Einstein College of Medicine in the Bronx, New York, where she first worked with tissue engineering, growing heart muscle cells in the laboratory.
Dr. Taylor was on the faculty of Duke University from 1991 to 2007, and then moved to University of Minnesota, where in 2008 her team published a landmark paper in Nature Medicine where they created new beating rat hearts using a combination of tissue engineering processes, first stripping the dead dying cells away from an existing heart (in a process called “de-cellularization”) leaving behind the hearts extracellular matrix and then re-seeding the matrix by injecting new young rat stem cells.